Mimicking an induced self phenotype by coating lymphomas with the NKp30 ligand B7-H6 promotes NK cell cytotoxicity

Journal of Immunology

Volumn 189, Issue 10, 2012, Pages 5037-5046

  Kellner, Christian ^a   Maurer, Tina ^a   Hallack, Daniela ^a   Repp, Roland ^a   Van De Winkel, Jan G J ^b,c   Parren, Paul W H I ^b   Valerius, Thomas ^a   Humpe, Andreas ^a   Gramatzki, Martin ^a   Peipp, Matthias ^a  

^a UNIVERSITY OF KIEL   (Germany)

^b GENMAB   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; COMPLEMENTARY DNA; FC RECEPTOR; FC RECEPTOR IIIA; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; RITUXIMAB; TRASTUZUMAB; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ARTICLE; BINDING AFFINITY; CHRONIC LYMPHATIC LEUKEMIA; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOLYSIS; DEGRANULATION; FLOW CYTOMETRY; LYMPHOMA; MOLECULAR MIMICRY; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; SEQUENCE HOMOLOGY;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; B7 ANTIGENS; CELL DEGRANULATION; CELL LINE, TUMOR; DRUG SYNERGISM; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; LYMPHOMA; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; RECEPTORS, IGG;

EID: 84868587481     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1201321     Document Type: Article

References (46)

1. Vivier, E., D. H. Raulet, A. Moretta, M. A. Caligiuri, L. Zitvogel, L. L. Lanier, W. M. Yokoyama, and S. Ugolini. 2011. Innate or adaptive immunity? The example of natural killer cells. Science 331: 44-49.
2. Caligiuri, M. A. 2008. Human natural killer cells. Blood 112: 461-469.
3. Raulet, D. H. 2004. Interplay of natural killer cells and their receptors with the adaptive immune response. Nat. Immunol. 5: 996-1002.
4. Kärre, K., H. G. Ljunggren, G. Piontek, and R. Kiessling. 1986. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 319: 675-678.
5. Moretta, A., C. Bottino, M. Vitale, D. Pende, C. Cantoni, M. C. Mingari, R. Biassoni, and L. Moretta. 2001. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu. Rev. Immunol. 19: 197-223.
6. Cerwenka, A., J. L. Baron, and L. L. Lanier. 2001. Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc. Natl. Acad. Sci. USA 98: 11521-11526.
7. Sivakamasundari, R., A. Raghunathan, C. Y. Zhang, R. R. Chowdhury, and S. M. Weissman. 2000. Expression and cellular localization of the protein encoded by the 1C7 gene: a recently described component of the MHC. Im-munogenetics 51: 723-732.
8. Pende, D., S. Parolini, A. Pessino, S. Sivori, R. Augugliaro, L. Morelli, E. Marcenaro, L. Accame, A. Malaspina, R. Biassoni, et al. 1999. Identification and molecular characterization of NKp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells. J. Exp. Med. 190: 1505-1516.
9. Tang, Q., B. Grzywacz, H. Wang, N. Kataria, Q. Cao, J. E. Wagner, B. R. Blazar, J. S. Miller, and M. R. Verneris. 2008. Umbilical cord blood T cells express multiple natural cytotoxicity receptors after IL-15 stimulation, but only NKp30 is functional. J. Immunol. 181: 4507-4515.
10. + T cells expressing the natural cytotoxicity receptor NKp30 for recognition of lymphoid leukemia cells. Blood 118: 992-1001.
11. Lanier, L. L. 2003. Natural killer cell receptor signaling. Curr. Opin. Immunol. 15: 308-314.
12. Sivori, S., S. Parolini, E. Marcenaro, R. Castriconi, D. Pende, R. Millo, and A. Moretta. 2000. Involvement of natural cytotoxicity receptors in human natural killer cell-mediated lysis of neuroblastoma and glioblastoma cell lines. J. Neu-roimmunol. 107: 220-225.
13. Byrd, A., S. C. Hoffmann, M. Jarahian, F. Momburg, and C. Watzl. 2007. Expression analysis of the ligands for the Natural Killer cell receptors NKp30 and NKp44. PLoS ONE 2: e1339.
14. Castriconi, R., A. Dondero, M. V. Corrias, E. Lanino, D. Pende, L. Moretta, C. Bottino, and A. Moretta. 2004. Natural killer cell-mediated killing of freshly isolated neuroblastoma cells: critical role of DNAX accessory molecule-1-poliovirus receptor interaction. Cancer Res. 64: 9180-9184.
15. Brandt, C. S., M. Baratin, E. C. Yi, J. Kennedy, Z. Gao, B. Fox, B. Haldeman, C. D. Ostrander, T. Kaifu, C. Chabannon, et al. 2009. The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. J. Exp. Med. 206: 1495-1503.
16. Pogge von Strandmann, E., V. R. Simhadri, B. von Tresckow, S. Sasse, K. S. Reiners, H. P. Hansen, A. Rothe, B. Böll, V. L. Simhadri, P. Borchmann, et al. 2007. Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells. Immunity 27: 965-974.
17. + NK cells as rapid producers of abundant IFN-g on activation. Proc. Natl. Acad. Sci. USA 108: 728-732.
18. Simhadri, V. R., K. S. Reiners, H. P. Hansen, D. Topolar, V. L. Simhadri, K. Nohroudi, T. A. Kufer, A. Engert, and E. Pogge von Strandmann. 2008. Dendritic cells release HLA-B-associated transcript-3 positive exosomes to regulate natural killer function. PLoS ONE 3: e3377.
19. Joyce, M. G., P. Tran, M. A. Zhuravleva, J. Jaw, M. Colonna, and P. D. Sun. 2011. Crystal structure of human natural cytotoxicity receptor NKp30 and identification of its ligand binding site. Proc. Natl. Acad. Sci. USA 108: 6223-6228.
20. Li, Y., Q. Wang, and R. A. Mariuzza. 2011. Structure of the human activating natural cytotoxicity receptor NKp30 bound to its tumor cell ligand B7-H6. J. Exp. Med. 208: 703-714.
21. Kaifu, T., B. Escalière, L. N. Gastinel, E. Vivier, and M. Baratin. 2011. B7-H6/NKp30 interaction: a mechanism of alerting NK cells against tumors. Cell. Mol. Life Sci. 68: 3531-3539.
22. Flies, D. B., and L. Chen. 2007. The new B7s: playing a pivotal role in tumor immunity. J. Immunother. 30: 251-260.
23. Nausch, N., and A. Cerwenka. 2008. NKG2D ligands in tumor immunity. On-cogene 27: 5944-5958.
24. Rey, J., C. Veuillen, N. Vey, R. Bouabdallah, and D. Olive. 2009. Natural killer and gd T cells in haematological malignancies: enhancing the immune effectors. Trends Mol. Med. 15: 275-284.
25. Stamova, S., M. Cartellieri, A. Feldmann, C. C. Bippes, H. Bartsch, R. Wehner, M. Schmitz, M. von Bonin, M. Bornhäuser, G. Ehninger, et al. 2011. Simultaneous engagement of the activatory receptors NKG2D and CD3 for retargeting of effector cells to CD33-positive malignant cells. Leukemia 25: 1053-1056.
26. von Strandmann, E. P., H. P. Hansen, K. S. Reiners, R. Schnell, P. Borchmann, S. Merkert, V. R. Simhadri, A. Draube, M. Reiser, I. Purr, et al. 2006. A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo. Blood 107: 1955-1962.
27. Kellner, C., D. Hallack, P. Glorius, M. Staudinger, S. Mohseni Nodehi, M. de Weers, J. G. van de Winkel, P. W. Parren, M. Stauch, T. Valerius, et al. 2012. Fusion proteins between ligands for NKG2D and CD20-directed single-chain variable fragments sensitize lymphoma cells for natural killer cell-mediated lysis and enhance antibody-dependent cellular cytotoxicity. Leukemia 26: 830-834.
28. Repp, R., C. Kellner, A. Muskulus, M. Staudinger, S. M. Nodehi, P. Glorius, D. Akramiene, M. Dechant, G. H. Fey, P. H. van Berkel, et al. 2011. Combined Fc-protein-and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC. J. Immunol. Methods 373: 67-78.
29. Oganesyan, V., C. Gao, L. Shirinian, H. Wu, and W. F. Dall'Acqua. 2008. Structural characterization of a human Fc fragment engineered for lack of effector functions. Acta Crystallogr. D Biol. Crystallogr. 64: 700-704.
30. Peipp, M., N. Simon, A. Loichinger, W. Baum, K. Mahr, S. J. Zunino, and G. H. Fey. 2001. An improved procedure for the generation of recombinant single-chain Fv antibody fragments reacting with human CD13 on intact cells. J. Immunol. Methods 251: 161-176.
31. Bruenke, J., B. Fischer, K. Barbin, K. Schreiter, Y. Wachter, K. Mahr, F. Titgemeyer, M. Niederweis, M. Peipp, S. J. Zunino, et al. 2004. A recombinant bispecific single-chain Fv antibody against HLA class II and FcgRIII (CD16) triggers effective lysis of lymphoma cells. Br. J. Haematol. 125: 167-179.
32. Peipp, M., J. J. Lammerts van Bueren, T. Schneider-Merck, W. W. Bleeker, M. Dechant, T. Beyer, R. Repp, P. H. van Berkel, T. Vink, J. G. van de Winkel, et al. 2008. Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells. Blood 112: 2390-2399.
33. Chou, T. C., and P. Talalay. 1984. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22: 27-55.
34. Teeling, J. L., R. R. French, M. S. Cragg, J. van den Brakel, M. Pluyter, H. Huang, C. Chan, P. W. Parren, C. E. Hack, M. Dechant, et al. 2004. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 104: 1793-1800.
35. Terme, M., E. Ullrich, N. F. Delahaye, N. Chaput, and L. Zitvogel. 2008. Natural killer cell-directed therapies: moving from unexpected results to successful strategies. Nat. Immunol. 9: 486-494.
36. Binyamin, L., R. K. Alpaugh, T. L. Hughes, C. T. Lutz, K. S. Campbell, and L. M. Weiner. 2008. Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy. J. Immunol. 180: 6392-6401.
37. Koh, C. Y., B. R. Blazar, T. George, L. A. Welniak, C. M. Capitini, A. Raziuddin, W. J. Murphy, and M. Bennett. 2001. Augmentation of antitumor effects by NK cell inhibitory receptor blockade in vitro and in vivo. Blood 97: 3132-3137.
38. Figueiredo, C., A. Seltsam, and R. Blasczyk. 2009. Permanent silencing of NKG2A expression for cell-based therapeutics. J. Mol. Med. 87: 199-210.
39. Delahaye, N. F., S. Rusakiewicz, I. Martins, C. Ménard, S. Roux, L. Lyonnet, P. Paul, M. Sarabi, N. Chaput, M. Semeraro, et al. 2011. Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat. Med. 17: 700-707.
40. Fuchs, A., M. Cella, E. Giurisato, A. S. Shaw, and M. Colonna. 2004. Cutting edge: CD96 (tactile) promotes NK cell-target cell adhesion by interacting with the poliovirus receptor (CD155). J. Immunol. 172: 3994-3998.
41. Martinez, E., J. A. Brzostowski, E. O. Long, and C. C. Gross. 2011. Cutting edge: NKG2D-dependent cytotoxicity is controlled by ligand distribution in the target cell membrane. J. Immunol. 186: 5538-5542.
42. Al-Hubeshy, Z. B., A. Coleman, M. Nelson, and M. R. Goodier. 2011. A rapid method for assessment of natural killer cell function after multiple receptor crosslinking. J. Immunol. Methods 366: 52-59.
43. Bryceson, Y. T., M. E. March, H. G. Ljunggren, and E. O. Long. 2006. Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Blood 107: 159-166.
44. Wu, J., Y. Song, A. B. Bakker, S. Bauer, T. Spies, L. L. Lanier, and J. H. Phillips. 1999. An activating immunoreceptor complex formed by NKG2D and DAP10. Science 285: 730-732.
45. Billadeau, D. D., J. L. Upshaw, R. A. Schoon, C. J. Dick, and P. J. Leibson. 2003. NKG2D-DAP10 triggers human NK cell-mediated killing via a Syk-independent regulatory pathway. Nat. Immunol. 4: 557-564.
46. 2 3 CD16] efficiently triggers effector cell-mediated lysis of malignant B cells. Leukemia. DOI: 10.1038/leu.2012.150.